Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Talphera Inc's Business Segments
Talphera Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Reportable Segments
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable Segments0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segments | $ 0 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segments0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segments | $ 0 | - |
Description of Talphera Inc
The company is a specialty pharmaceutical firm focused on developing and commercializing therapies for medically supervised settings. Its primary product candidate is Niyad (nafamostat mesylate), a lyophilized vial formulation intended as a regional anticoagulant during continuous renal replacement therapy (CRRT) for adult patients, particularly those with acute kidney injury (AKI). Niyad is being studied under an Investigational Device Exemption (IDE) and has received Breakthrough Device Designation from the FDA. A registrational trial is ongoing and expected to complete in 2026. The company is also developing LTX-608, a nafamostat formulation for direct intravenous infusion targeting indications including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), acute pancreatitis, and antiviral treatment. Nafamostat has been approved and used in Japan and South Korea for over 30 years for similar indications. The company acquired Lowell Therapeutics, Inc. in January 2022, which included the Niyad and LTX-608 assets. Upon completion of the trial, the company plans to submit a Premarket Approval (PMA) application for Niyad. The market opportunity involves addressing limitations of current anticoagulants such as heparin and citrate used during CRRT, with nafamostat potentially offering regional anticoagulation with a short half-life and fewer safety concerns.
Talphera Inc. is a company that operates in the biotechnology and life sciences sector, focusing on advancing precision medicine. The organizations segments, products, and services are aimed at enhancing drug development processes and personalized healthcare solutions.
Segments
1. Biotech Research and Development: This segment is dedicated to the discovery and validation of new therapeutic compounds. It involves extensive preclinical and clinical research to identify potential treatment pathways for various diseases. Talphera employs cutting-edge technologies and methodologies in genomics, bioinformatics, and systems biology to drive innovation in drug discovery.
2. Clinical Trials Management: Talphera offers comprehensive services for the design, management, and execution of clinical trials. This includes recruiting and managing study participants, conducting site evaluations, and ensuring compliance with regulatory requirements. The clinical trials management segment also emphasizes patient engagement and retention strategies to facilitate successful outcomes.
3. Genomic Analysis and Biomarker Discovery: This segment focuses on leveraging genomic data to discover biomarkers that can be used for disease diagnosis, prognosis, and treatment stratification. Talphera utilizes advanced sequencing technologies and bioinformatics tools to analyze genetic variations and identify actionable insights that can inform therapeutic decisions.
4. Regulatory Affairs Consulting: Talphera provides consulting services to help companies navigate the complex landscape of regulatory requirements related to drug development. This includes guidance on designing clinical trial protocols, submitting Investigational New Drug (IND) applications, and preparing for regulatory agency meetings.
5. Data Analytics and Software Solutions: This segment develops and offers software platforms that facilitate data management and analysis in both clinical and research settings. The tools are designed to support various functions, including data integration, visualization, and statistical analysis, thereby helping stakeholders make informed decisions based on comprehensive evidence.
Products
1. Precision Drug Development Platforms: Talphera has developed proprietary platforms that integrate multi-omics data to optimize drug development processes. These platforms aim to enhance target selection and patient stratification, thereby increasing the likelihood of clinical success.
2. Biomarker Discovery Kits: The company provides kits that enable researchers to identify and validate biomarkers associated with specific diseases. These kits offer a streamlined approach to biomarker discovery, allowing for more efficient research outcomes.
3. Clinical Trial Management Software: Talphera’s software solutions streamline clinical trial operations by automating key tasks such as data collection, monitoring, and reporting. Designed for both sponsors and clinical sites, it enhances collaboration and improves trial efficiency.
4. Genomic Sequencing Services: Talphera offers comprehensive genomic sequencing services for a broad range of applications, from basic research to clinical diagnostics. These services include whole-genome sequencing, targeted sequencing, and RNA sequencing, providing vital information for research and therapeutic applications.
Services
1. Consultative Drug Development Services: Talphera works closely with pharmaceutical and biotech companies to provide end-to-end consultative services in drug development. This includes strategic planning, execution of research, and assistance in optimizing development paths to ensure regulatory success.
2. Patient Recruitment and Retention Solutions: Recognizing the challenges associated with recruiting participants for clinical trials, Talphera provides tailored strategies to enhance recruitment efforts. This may involve using technology for outreach, patient education, and community engagement.
3. Training and Education Programs: Talphera offers training programs designed to educate both internal teams and external partners about new technologies, methodologies, and regulatory requirements in the field of drug development. These programs aim to elevate knowledge and skills essential for successful project execution.
4. Data Analytics Consulting: The company provides analytical consulting services to help clients interpret complex datasets, derive actionable insights, and make data-driven decisions. This service includes data visualization, statistical analysis, and predictive modeling.
5. Partnership Programs: Talphera often engages in collaboration with academic institutions, research organizations, and industry partners to foster innovation. These partnerships may include co-development projects, technology licensing agreements, or joint research initiatives.
In summary, Talphera Inc. encompasses a diverse array of segments, products, and services that aim to enhance the landscape of drug development and precision medicine. Through their innovative approaches and comprehensive solutions, Talphera is positioned to make significant contributions to the biotechnology field and ultimately improve patient outcomes.
Segments
1. Biotech Research and Development: This segment is dedicated to the discovery and validation of new therapeutic compounds. It involves extensive preclinical and clinical research to identify potential treatment pathways for various diseases. Talphera employs cutting-edge technologies and methodologies in genomics, bioinformatics, and systems biology to drive innovation in drug discovery.
2. Clinical Trials Management: Talphera offers comprehensive services for the design, management, and execution of clinical trials. This includes recruiting and managing study participants, conducting site evaluations, and ensuring compliance with regulatory requirements. The clinical trials management segment also emphasizes patient engagement and retention strategies to facilitate successful outcomes.
3. Genomic Analysis and Biomarker Discovery: This segment focuses on leveraging genomic data to discover biomarkers that can be used for disease diagnosis, prognosis, and treatment stratification. Talphera utilizes advanced sequencing technologies and bioinformatics tools to analyze genetic variations and identify actionable insights that can inform therapeutic decisions.
4. Regulatory Affairs Consulting: Talphera provides consulting services to help companies navigate the complex landscape of regulatory requirements related to drug development. This includes guidance on designing clinical trial protocols, submitting Investigational New Drug (IND) applications, and preparing for regulatory agency meetings.
5. Data Analytics and Software Solutions: This segment develops and offers software platforms that facilitate data management and analysis in both clinical and research settings. The tools are designed to support various functions, including data integration, visualization, and statistical analysis, thereby helping stakeholders make informed decisions based on comprehensive evidence.
Products
1. Precision Drug Development Platforms: Talphera has developed proprietary platforms that integrate multi-omics data to optimize drug development processes. These platforms aim to enhance target selection and patient stratification, thereby increasing the likelihood of clinical success.
2. Biomarker Discovery Kits: The company provides kits that enable researchers to identify and validate biomarkers associated with specific diseases. These kits offer a streamlined approach to biomarker discovery, allowing for more efficient research outcomes.
3. Clinical Trial Management Software: Talphera’s software solutions streamline clinical trial operations by automating key tasks such as data collection, monitoring, and reporting. Designed for both sponsors and clinical sites, it enhances collaboration and improves trial efficiency.
4. Genomic Sequencing Services: Talphera offers comprehensive genomic sequencing services for a broad range of applications, from basic research to clinical diagnostics. These services include whole-genome sequencing, targeted sequencing, and RNA sequencing, providing vital information for research and therapeutic applications.
Services
1. Consultative Drug Development Services: Talphera works closely with pharmaceutical and biotech companies to provide end-to-end consultative services in drug development. This includes strategic planning, execution of research, and assistance in optimizing development paths to ensure regulatory success.
2. Patient Recruitment and Retention Solutions: Recognizing the challenges associated with recruiting participants for clinical trials, Talphera provides tailored strategies to enhance recruitment efforts. This may involve using technology for outreach, patient education, and community engagement.
3. Training and Education Programs: Talphera offers training programs designed to educate both internal teams and external partners about new technologies, methodologies, and regulatory requirements in the field of drug development. These programs aim to elevate knowledge and skills essential for successful project execution.
4. Data Analytics Consulting: The company provides analytical consulting services to help clients interpret complex datasets, derive actionable insights, and make data-driven decisions. This service includes data visualization, statistical analysis, and predictive modeling.
5. Partnership Programs: Talphera often engages in collaboration with academic institutions, research organizations, and industry partners to foster innovation. These partnerships may include co-development projects, technology licensing agreements, or joint research initiatives.
In summary, Talphera Inc. encompasses a diverse array of segments, products, and services that aim to enhance the landscape of drug development and precision medicine. Through their innovative approaches and comprehensive solutions, Talphera is positioned to make significant contributions to the biotechnology field and ultimately improve patient outcomes.